Lifecore Biomedical (LFCR) closed at $6.36 on November 6, 2026, down 0.6% from the previous close, on volume of 771,648 shares (30-day average 671,538).
Data as of November 6, 2026.
Lifecore Biomedical Receives Antitrust Clearance for Proposed Merger
TipRanks (Thu, 5-Nov 8:52 AM ET)
Lifecore Biomedical GAAP EPS of -$1.08 misses by $0.98, revenue of $25.3M misses by $13.31M
Seeking Alpha News (Thu, 5-Nov 3:28 AM ET)
TipRanks (Wed, 4-Nov 12:50 PM ET)
Globe Newswire (Wed, 4-Nov 8:46 AM ET)
Globe Newswire (Wed, 4-Nov 7:05 AM ET)
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 3-Nov 7:09 PM ET)
PRNewswire (Tue, 3-Nov 12:18 PM ET)
Globe Newswire (Fri, 30-Oct 10:49 AM ET)
Lifecore Biomedical to Participate at Upcoming Industry Conferences
Globe Newswire (Wed, 7-Oct 4:05 PM ET)
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 5-Oct 10:40 PM ET)
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
Lifecore Biomedical trades on the NASDAQ stock market under the symbol LFCR.
As of November 6, 2026, LFCR stock price declined to $6.36 with 771,648 million shares trading.
LFCR has a beta of 2.27, meaning it tends to be more sensitive to market movements. LFCR has a correlation of 0.11 to the broad based SPY ETF.
LFCR has a market cap of $241.08 million. This is considered a Small Cap stock.
Last quarter Lifecore Biomedical reported $25 million in Revenue and -$1.08 earnings per share. This fell short of revenue expectation by $-245,120 and missed earnings estimates by -$.78.
In the last 3 years, LFCR traded as high as $8.98 and as low as $3.63.
The top ETF exchange traded funds that LFCR belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
LFCR has underperformed the market in the last year with a return of -6.1%, while SPY returned +9.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LFCR shares. However, LFCR has outperformed the market in the last 3 month and 2 week periods, returning +43.2% and -0.2%, while SPY returned -4.2% and -3.8%, respectively. This indicates LFCR has been having a stronger performance recently.
LFCR support price is $6.35 and resistance is $6.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LFCR shares will trade within this expected range on the day.